Advertisement

Digestive Diseases and Sciences

, Volume 47, Issue 4, pp 741–745 | Cite as

Effects of Gabexate Mesilate, a Protease Inhibitor, on Human Sphincter of Oddi Motility

  • Vincenzo Di Francesco
  • Alberto Mariani
  • Giampaolo Angelini
  • Enzo Masci
  • Luca Frulloni
  • Giorgio Talamini
  • Sandro Passaretti
  • Pieralberto Testoni
  • Giorgio Cavallini
Article

Abstract

Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis. In dogs gabexate inhibits sphincter of Oddi motility but no data are available in humans. The aim of this study was to verify by manometry the action of gabexate on human sphincter of Oddi motility. We enrolled 12 patients with idiopathic recurrent pancreatitis (eight males, five females, mean age 46 ± 8 years). Standard preendoscopic sphincter of Oddi manometry was done in basal conditions and during infusion of gabexate 20 mg/min: basal pressure, amplitude and frequency of phasic contractions, and motility index (amplitude per frequency) were calculated before and after gabexate injection. Statistical analysis was performed by using Wilcoxon rank test for paired data. Six patients had a manometric diagnosis of stenosis (basal pressure greater than 40 mm Hg); six had normal findings. Phasic activity was not evaluable in five patients with stenosis. Basal pressure was unaffected by drug infusion, while gabexate caused a significant reduction of phasic activity, both in terms of frequency (4.5 ± 1 vs 3.6 ± 1; P < 0.05) and amplitude (157.4 ± 44 vs 80.0 ± 32; P < 0.05) of contractions. Motility index was reduced on average by 49%. In conclusion, this pilot study confirms, in patients with acute recurrent pancreatitis, the inhibitory action of gabexate on sphincter of Oddi motility already described in dogs. This action needs to be revaluated at therapeutic dosages. On the other hand, prophylactic use of the drug should be avoided during sphincter of Oddi manometry, in order to avoid false negative results.

sphincter of Oddi motility antiprotease recurrent pancreatitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S: Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, C1 esterase. Biochim Biophys Acta 484:417–422, 1977PubMedGoogle Scholar
  2. 2.
    Ito T, Kimura T, Furukawa M, Yamaguchi H, Goto M, Nakano I, Nawata H: Protective effects of gabexate mesilate on acute pancreatitis induced by tacrolimus (FK-506) in rats in which the pancreas was stimulated by caerulein. J Gastroenterol 29(3):305–313, 1994PubMedGoogle Scholar
  3. 3.
    Wakayama T, Itoh T, Shibayama K, Idezuki Y: Prevention of spread of experimental acute pancreatitis by intraductal administration of a synthetic inhibitor in dogs. Am J Gastroenterol 84:272–278, 1989PubMedGoogle Scholar
  4. 4.
    Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N: Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci 40(4):734–738, 1995PubMedGoogle Scholar
  5. 5.
    Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V: Gabexate mesilate in the prevention of pancreatic damage induced by endoscopic retrograde cholangio pancreatography. N Engl J Med 335(13):919–923, 1996PubMedGoogle Scholar
  6. 6.
    Yamasato T, Mori M, Mimura H, Hamazaki K, Kashino H, Gouchi A, Okabayashi T, Tsuge H, Miyake J, Suga M: Effects of gabexatate mesilate (FOY) on the gallbladder, sphincter of Oddi and duodenum of the normal and gastrectomized dogs. J Smooth Muscle Res 27:87–96, 1991PubMedGoogle Scholar
  7. 7.
    Behar J, Biancani P: Neural control of the sphincter of Oddi. Gastroenterology 86:134–141, 1984PubMedGoogle Scholar
  8. 8.
    Worthley CS, Baker RA, Iannos J, Saccone GT, Toouli J: Human fasting and postprandial sphincter of Oddi motility. Br J Surg 76:709–714, 1989PubMedGoogle Scholar
  9. 9.
    Toouli J, Hogan WJ, Geenen JW, Dodds WJ, Arndorfer RC: Action of cholecystokinin octapeptide on sphincter of Oddi pressure and phasic wave activity in man. Surgery 92:497–503, 1982PubMedGoogle Scholar
  10. 10.
    Sand J, Tainio H, Nordback I: Peptidergic innervation of human sphincter of Oddi. Dig Dis Sci 39:293–300, 1994PubMedGoogle Scholar
  11. 11.
    Sand J, Arvola P, Jantti P, Oja S, Singaram C, Baer G, Pasricha PJ, Nordback I: The inhibitory role of nitric oxide in the control of porcine and human sphincter of Oddi activity. Gut 41(3):375–380, 1997PubMedGoogle Scholar
  12. 12.
    Pasricha PJ: Prevention of ERCP-induced pancreatitis: success at last. Gastroenterology 112:1415–1417, 1997PubMedGoogle Scholar
  13. 13.
    Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP: Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 33:1129–1133, 1992PubMedGoogle Scholar
  14. 14.
    Di Francesco V, Angelini G, Bovo P, Casarini MB, Filippini M, Vaona B, Frulloni L, Rigo L, Brunori MP, Cavallini G: Effect of octreotide on sphincter of Oddi motility in patients with acute recurrent pancreatitis. A manometric study. Dig Dis Sci 41:2392–2396, 1996PubMedGoogle Scholar
  15. 15.
    Rolny P, Anderberg B, Ihse I, Lindstrom E, Oilason G, Arvill A: Pancreatitis after sphincter of Oddi manometry. Gut 31:821–824, 1990PubMedGoogle Scholar
  16. 16.
    Nishijima MK, Takezawa J, Taenaka N, Shimada Y, Yoshiya I: Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res 31:279–284, 1983PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Vincenzo Di Francesco
    • 1
  • Alberto Mariani
    • 2
  • Giampaolo Angelini
    • 3
  • Enzo Masci
    • 2
  • Luca Frulloni
    • 3
  • Giorgio Talamini
    • 3
  • Sandro Passaretti
    • 2
  • Pieralberto Testoni
    • 2
  • Giorgio Cavallini
    • 3
  1. 1.Department of Biomedical and Surgical SciencesUniversity of VeronaVeronaItaly
  2. 2.Department of Biomedical Science, Division of Gastroenterology, IRCCSUniversity of MilanoSan RaffaeleItaly
  3. 3.Department of Surgery and GastroenterologyUniversity of VeronaVeronaItaly

Personalised recommendations